Core Viewpoint - Allegro MicroSystems, Inc. (ALGM) has been upgraded to a Zacks Rank 2 (Buy), indicating an upward trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors utilize earnings estimates to determine the fair value of a company's shares, impacting stock price through their trading activities [4]. Business Outlook - The upgrade in Allegro MicroSystems' rating suggests an improvement in the company's underlying business, which could lead to higher stock prices as investors respond positively [5][10]. - For the fiscal year ending March 2026, Allegro MicroSystems is expected to earn $0.53 per share, with a 1.9% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [7][9]. - Allegro MicroSystems' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Core Viewpoint - TAL Education (TAL) shares have increased by 8.2% over the past four weeks, closing at $12.25, with a mean price target of $15.59 indicating a potential upside of 27.3% [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $2.15, where the lowest estimate is $11.54 (5.8% decline) and the highest is $18.00 (46.9% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [2][9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about TAL's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 74%, with three estimates moving higher and no negative revisions [12] Zacks Rank and Investment Potential - TAL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of TAL's potential gains, the implied direction of price movement appears to be a useful guide [14]

Group 1 - Arcus Biosciences, Inc. (RCUS) shares have increased by 1.2% over the past four weeks, closing at $21.96, with a mean price target of $34.6 indicating a potential upside of 57.6% [1] - The average of 10 short-term price targets ranges from a low of $20.00 to a high of $52.00, with a standard deviation of $10.17, suggesting variability in analyst estimates [2] - Analysts are optimistic about RCUS's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1% over the last 30 days, with one estimate moving higher and no negative revisions [12] - RCUS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide guidance on the direction of price movement [14]

Core Viewpoint - Sunrun (RUN) shares have shown a modest increase of 0.9% over the past month, closing at $18.47, with analysts suggesting a potential upside of 25.3% based on a mean price target of $23.14 [1] Price Targets and Analyst Estimates - The mean estimate consists of 20 short-term price targets with a standard deviation of $2.72, indicating variability among analysts; the lowest estimate is $19.00 (2.9% increase), while the highest is $30.00 (62.4% increase) [2] - A low standard deviation suggests strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding Sunrun's earnings prospects, as indicated by a significant increase in earnings estimate revisions, which correlates with potential stock price movements [11] - The Zacks Consensus Estimate for the current year has surged by 469.7% over the past month, with no negative revisions, indicating strong positive sentiment [12] Zacks Rank and Investment Potential - Sunrun currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a useful guide for potential price movements [14]

Core Viewpoint - SkyWest (SKYW) shares have shown no change over the past four weeks, closing at $101.47, but analysts suggest a potential upside of 26.5% based on a mean price target of $128.33 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $12.55, indicating variability among analysts [2] - The lowest estimate is $112.00, suggesting a 10.4% increase, while the highest estimate is $150.00, indicating a potential surge of 47.8% [2] - A smaller standard deviation reflects greater agreement among analysts regarding price movement [2][9] Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings estimates higher, which is a positive indicator for potential stock upside [4][11] - Over the last 30 days, three earnings estimates have increased, leading to a 3.1% rise in the Zacks Consensus Estimate [12] - SkyWest holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as analysts' ability to set accurate targets has been questioned [3][10] - Price targets can be influenced by business relationships, leading to potentially inflated estimates [8][9]

Core Viewpoint - Kforce (KFRC) has shown an 8.3% increase in stock price over the past four weeks, with a mean price target of $45.13 indicating a potential upside of 27.9% from the current price of $35.28 [1] Price Targets - The average price target for KFRC ranges from a low of $34.50 to a high of $71.00, with a standard deviation of $17.31, indicating variability in analyst estimates [2] - The lowest estimate suggests a decline of 2.2%, while the highest indicates a potential upside of 101.3% [2] - A low standard deviation signifies greater agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts are optimistic about KFRC's earnings prospects, as indicated by upward revisions in EPS estimates, which historically correlate with stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.2%, with one estimate moving higher and no negative revisions [12] Zacks Rank - KFRC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of KFRC's potential gains, it does provide a directional guide for price movement [14]

Group 1 - The stock of Bitdeer Technologies Group (BTDR) closed at $12.96, reflecting an 8.3% gain over the past four weeks, with a mean price target of $29.73 indicating a potential upside of 129.4% [1] - The mean estimate consists of 11 short-term price targets with a standard deviation of $7.04, where the lowest estimate is $14.00 (an 8% increase) and the highest is $40.00 (a 208.6% increase) [2] - Analysts show strong agreement on BTDR's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for BTDR's current year earnings has increased by 29.3% over the past month, with no negative revisions [12] - BTDR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does suggest a positive direction for price movement [14]

分组1 - Janux Therapeutics, Inc. (JANX) shares have increased by 1.8% over the past four weeks, closing at $13.99, with a mean price target of $58.65 indicating a potential upside of 319.2% [1] - The mean estimate consists of 17 short-term price targets with a standard deviation of $34.53, where the lowest estimate is $12.00 (14.2% decline) and the highest is $150.00 (972.2% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] 分组2 - The Zacks Consensus Estimate for the current year has risen by 0.2% over the past month, with one estimate increasing and no negative revisions [12] - JANX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - IperionX Limited (IPX) shows significant potential for upside, with a mean price target of $64 indicating a 28.2% increase from its current price of $49.93, following a 25.1% gain over the past four weeks [1] Price Targets and Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $8.72, where the lowest estimate of $58.00 suggests a 16.2% increase, and the highest estimate of $74.00 indicates a potential surge of 48.2% [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Analyst Sentiment and Earnings Estimates - Analysts exhibit growing optimism about IPX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with near-term stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 8.3%, with one estimate increasing and no negative revisions [12] Zacks Rank and Investment Potential - IPX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside in the near term [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - KalVista Pharmaceuticals, Inc. (KALV) has seen a 1% increase in share price over the past four weeks, closing at $15.61, with analysts suggesting a potential upside of 116.4% based on a mean price target of $33.78 [1] Price Targets - The average price target from nine analysts ranges from a low of $22.00 to a high of $39.00, indicating a standard deviation of $5.4, which reflects the variability of estimates [2] - The lowest estimate suggests a 40.9% increase from the current price, while the highest estimate indicates a 149.8% upside [2] Analyst Sentiment - Analysts show strong agreement regarding KALV's potential for better earnings, as indicated by positive revisions in earnings estimates, which historically correlate with stock price movements [4][11] - The Zacks Consensus Estimate for the current year has risen by 12.6% over the past month, with two estimates increasing and no negative revisions [12] Zacks Rank - KALV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13] Conclusion on Price Movement - While the consensus price target may not be entirely reliable, the direction indicated by these targets appears to be a useful guide for potential price movement [14]